Across TCGA pan-cancer cohorts, TXNDC12-AS1 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of TXNDC12-AS1’s most consistent transcriptional readouts.
The strongest signal is observed in bladder urothelial carcinoma (BLCA), where TXNDC12-AS1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TXNDC12-AS1 is over-expressed in tumor, although a few such as COAD show the opposite, repressed pattern.
BLCA, HNSC, and STAD are the cancer types where TXNDC12-AS1 tumor–normal differential expression is most reproducible.
RNA tumor vs normal associations by lineage
Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TXNDC12-AS1 RNA (log2); positive values indicate higher expression in tumor. p-values are from the differential-expression test.